AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7489218
Drug: Epidural spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural spinal cord electrical stimulation (ESES) in addition to best medical treatment
Trial: 7489218
Drug: ESES treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESES treatment
Trial: 1844568
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (100 mg per day for 8 weeks)
Trial: 1844568
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mg per day for 8 weeks)
Trial: 6786412
Drug: 5 percent
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 percent mannitol solution orally
Trial: 6786412
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 10 percent mannitol and isotonic saline
Trial: 10626718
Drug: Midazolam premedication
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam premedication (2 mg im 30 min before operation)
Trial: 8204811
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of nitric oxide (NO) at concentrations of 2 to 25 ppm for 6 to 10 minutes
Trial: 28719485
Drug: Application of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of heat gel pack after removal of EMLA cream (treatment group)
Trial: 28719485
Drug: No application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No application of heat gel pack (control group)
Trial: 16896965
Drug: 2/4‐mg gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2/4‐mg gum + 15‐mg patch (G/P)
Trial: 16896965
Drug: 2/4‐mg lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2/4‐mg lozenges + 15‐mg patch (L/P)
Trial: 16896965
Drug: Inhaler +
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaler + 15‐mg patch (I/P)
Trial: 16896965
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg + 15‐mg patches (P/P)
Trial: 16896965
Drug: Acute‐patch combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute‐patch combinations (A/P)
Trial: 11889328
Drug: Intravenous salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous salbutamol (15 microg/kg as a single bolus over 10 mins)
Trial: 11889328
Drug: Intravenous salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous salbutamol plus ipratropium bromide
Trial: 28076829
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5mg once daily + Cabergoline 0.5mg/week for 12 weeks
Trial: 27701629
Drug: Enhanced Conversational
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Conversational Recast treatment (30-min session, massed condition)
Trial: 27701629
Drug: Enhanced Conversational
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Conversational Recast treatment (3 sessions of 10-min each, spaced condition)
Trial: 27701629
Drug: Enhanced Conversational
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Conversational Recast treatment (both conditions)
Trial: 11944007
Drug: Gelofusine (Gel)
RxNorm normalized name: Gelofusine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelofusine (Gel)
Trial: 11944007
Drug: Gel vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel vs Sal
Trial: 7695302
Drug: Oral co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral co-trimoxazole plus topical fusidic acid
Trial: 2636671
Drug: New essential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New essential amino acid formulation (BS695), enriched with valine and threonine, low in phenylalanine and methionine, 3.65 g of nitrogen, i.v. three times per week for six months.
Trial: 2636671
Drug: Standard amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard amino acid solution (control group), 3.65 g of nitrogen, i.v. three times per week for six months.
Trial: 336670
Drug: Cyclandelate (1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclandelate (1,600 mg/day in fractional doses)
Trial: 25108576
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (4 capsules daily, 1.01 g EPA + 0.67 g DHA)
Trial: 19295240
Drug: Enzymatically modified
RxNorm normalized name: Isoquercetin enzymatically modified
DrugBank: Isoquercitrin (DB16403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzymatically modified isoquercitrin (EMIQ) 100 mg, two capsules daily for 8 weeks
Trial: 2487550
Drug: Hydrochlorothiazide/amiloride (diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide/amiloride (diuretic therapy)
Trial: 28556418
Drug: KHK4083 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KHK4083 1.0 mg/kg SC
Trial: 28556418
Drug: KHK4083 0.03,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KHK4083 0.03, 0.1, 0.3, 1.0, 3.0, and 10 mg/kg IV
Trial: 28556418
Drug: KHK4083 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KHK4083 (various doses)
Trial: 9576302
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (low dose, < or =20 mg per day)
Trial: 9576302
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (low dose)
Trial: 2959438
Drug: metformin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin therapy
Trial: 2959438
Drug: ultralente insulin
RxNorm normalized name: ultralente insulin, beef
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ultralente insulin
Trial: 2959438
Drug: ultralente insulin
RxNorm normalized name: ultralente insulin, beef
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ultralente insulin alone
Trial: 2959438
Drug: ultralente and
RxNorm normalized name: INSULIN,ULTRALENTE,HUMAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ultralente and soluble insulin
Trial: 30526582
Drug: Papaya fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaya fortified porridge (300 ml daily)
Trial: 30526582
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg one-time dosage)
Trial: 25239451
Drug: Topical propolis
RxNorm normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical propolis
Trial: 19841932
Drug: Beta-alanine supplementation
RxNorm normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine supplementation (4.8 g/day for 4 weeks)
Trial: 18390439
Drug: Calcium fumarate
RxNorm normalized name: calcium fumarate
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium fumarate tablets
Trial: 18390439
Drug: Calcium gluconate
RxNorm normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium gluconate tablets
Trial: 11811565
Drug: Raloxifene HCl
RxNorm normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene HCl (120 mg)
Trial: 11811565
Drug: Raloxifene HCl
RxNorm normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene HCl (60 mg)
Trial: 9892858
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of alcohol (BAC 0.03%)
Trial: 3514193
Drug: Biosynthetic growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic growth hormone (methionyl-hGH) administered to group I (32 children) with high ECP content
Trial: 3514193
Drug: Biosynthetic growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic growth hormone (methionyl-hGH) administered to group II (12 children) with reduced ECP content
Trial: 3514193
Drug: Biosynthetic growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic growth hormone (methionyl-hGH) administered to group III (11 children) with almost ECP-free preparations
Trial: 3514193
Drug: High antibody
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High antibody titres against ECP and hGH in group I
Trial: 26389639
Drug: Oral-methylphenidate
RxNorm normalized name: Methylphenidan
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-methylphenidate
Trial: 18452433
Drug: Asiaticoside-containing cream
RxNorm normalized name: asiaticoside
DrugBank: Asiaticoside (DB14081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asiaticoside-containing cream applied twice a day for 12 weeks
Trial: 12713209
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (different 4-week summer day camp + monthly home Internet intervention)
Trial: 7495976
Drug: Octavi S/D+heat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octavi S/D+heat treatment
Trial: 6244679
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with VM 26 and CCNU once every four weeks, commencing four weeks after the completion of radiotherapy.
Trial: 31732883
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (Fluoride then CPP-ACP, n=39)
Trial: 30714336
Drug: Phaco-EX-PRESS P50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phaco-EX-PRESS P50 with mitomycin C (0.2 mg/ml for 2 min)
Trial: 30714336
Drug: Phaco-NPDS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phaco-NPDS with Esnoper V2000 and mitomycin C (0.2 mg/ml for 2 min)
Trial: 26003782
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel 75mg/d
Trial: 23093541
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg prednisone over 5 days
Trial: 21641867
Drug: Continuous oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous oxaliplatin and fluoropyrimidine combination chemotherapy (arm A)
Trial: 21641867
Drug: Intermittent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent chemotherapy (arm C)
Trial: 21641867
Drug: Continuous chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous chemotherapy (arm A)
Trial: 9493662
Drug: Cathepsin G-like
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathepsin G-like activities
Trial: 3594105
Drug: Papaverine and
RxNorm normalized name: Papaverine and derivatives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine and phentolamine (30 mg papaverine and 1 mg phentolamine, 2 ml injection)
Trial: 3594105
Drug: Saline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (2 ml injection)
Trial: 31793041
Drug: MAL-photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAL-photodynamic therapy (MAL-PDT)
Trial: 31793041
Drug: ingenol mebutate
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ingenol mebutate gel (IMB)
Trial: 31793041
Drug: diclofenac plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac plus hyaluronate gel (DHA)
Trial: 29689257
Drug: Diphenhydramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (50 mg IV)
Trial: 23632672
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia with peri-articular injection of bupivacaine, morphine, and methylprednisolone.
Trial: 12859221
Drug: Sequential high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential high dose chemotherapy (HDC) with granulocyte colony-stimulating factor (filgrastim) and stem cell support
Trial: 9001371
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (1.62 g/d)
Trial: 1309944
Drug: Continuous estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous estradiol valerate (2 mg) plus cyproterone acetate (1 mg)
Trial: 1309944
Drug: Sequential estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential estradiol valerate (2 mg) plus levonorgestrel (75 micrograms)
Trial: 6734703
Drug: Theolin Retard
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theolin Retard 300 mg (sustained release tablet)
Trial: 6734703
Drug: Intravenous aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous aminophylline (reference material)
Trial: 30955455
Drug: 3 mg.kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg.kg-1 caffeine (CAF3)
Trial: 30955455
Drug: 6 mg.kg-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg.kg-1 caffeine (CAF6)
Trial: 27293053
Drug: Single intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intramuscular injection of bone marrow mononuclear cells (n = 11)
Trial: 27293053
Drug: Four intramuscular
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four intramuscular injections of bone marrow mononuclear cells (n = 11)
Trial: 27293053
Drug: Both single
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both single and four injections of bone marrow mononuclear cells
Trial: 19576318
Drug: Eptifibatide plus
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide plus a heparin product
Trial: 18277670
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g in 250 ml normal saline, infused before tourniquet deflation and again 3 hours later)
Trial: 18277670
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (250 ml infused intravenously)
Trial: 15277964
Drug: Rehabilitation (physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation (physical and occupational therapy sessions five times per week for 24.8 +/- 8.1 days)
Trial: 9807208
Drug: Intensive preoperative
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive preoperative radiotherapy (IPRT) combined with postoperative chemo- and hormonal therapy
Trial: 7815697
Drug: Continuous interpleural
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous interpleural infusion of 0.5% bupivacaine at the rate of 5 ml.h‐1
Trial: 7815697
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion of 0.25% bupivacaine and 0.025 buprenorphine at the rate of 1 ml.h‐1
Trial: 31112383
Drug: Cisatracurium continuous
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisatracurium continuous infusion (median duration 47.8 hours, median dose 1807 mg) with deep sedation
Trial: 31112383
Drug: Cisatracurium continuous
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisatracurium continuous infusion
Trial: 28492492
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein supplement (PRO)
Trial: 28492492
Drug: Maltodextrin supplement
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin supplement (CHO)
Trial: 21967071
Drug: Nalmefene 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 80 mg/day
Trial: 23910665
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg on day 7
Trial: 19267709
Drug: Metformin 1
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1 g x two times daily
Trial: 19267709
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir before bedtime
Trial: 19267709
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 30 before dinner
Trial: 19267709
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart before main meals and insulin detemir before bedtime
Trial: 11730741
Drug: Luteal phase
RxNorm normalized name: Nuphar lutea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteal phase support with vaginal progesterone beginning on day 6 after oocyte retrieval (GnRH agonist group)
Trial: 11730741
Drug: Luteal phase
RxNorm normalized name: Nuphar lutea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteal phase support with vaginal progesterone beginning on day 3 after oocyte retrieval (GnRH agonist group)
Trial: 3303278
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aerosol 400 micrograms once daily
Trial: 3303278
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aerosol 200 micrograms twice daily
Trial: 22882572
Drug: Same-day discharge
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day discharge with remote monitoring for 24 hours after ICD implant
Trial: 12383667
Drug: Azithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (250 mg daily for bodyweight ≤40 kg; 500 mg daily for bodyweight >40 kg)
Trial: 12840867
Drug: Theophylline (Protheo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (Protheo, 400 mg, qd)
Trial: 8772970
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate 2 gm bolus
Trial: 8772970
Drug: Intravenous verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous verapamil 5 mg
Trial: 6259922
Drug: Liquid glucose
RxNorm normalized name: Liquid glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid glucose formula (75 g carbohydrate)
Trial: 6259922
Drug: Brown rice
RxNorm normalized name: Brown rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brown rice (75 g carbohydrate)
Trial: 6259922
Drug: Pinto beans
RxNorm normalized name: Bean
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinto beans (75 g carbohydrate)
Trial: 6259922
Drug: All Bran
RxNorm normalized name: All bran loaf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All Bran (75 g carbohydrate)
Trial: 31653011
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement plus physical activity
Trial: 24660837
Drug: Parenteral n‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral n‐3 fatty acids (2 ml/kg/day of a lipid emulsion containing highly refined fish oil for 7 days)
Trial: 24660837
Drug: Parenteral n‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral n‐3 fatty acids
Trial: 19083199
Drug: Synbiotic 2000
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic 2000 FORTE (twice a day)
Trial: 17720993
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Urocortin 2 (25 microg)